Dr. Karen Reckamp, City of Hope Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.

[powerpress]

Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

[powerpress]

Drs. Ross Camidge and Corey Langer discuss which patients with advanced NSCLC they would recommend should have a repeat biopsy if their initial tissue sample doesn't have sufficient tissue for molecular testing.

[powerpress]

Dr. Sarah Goldberg reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

[powerpress]

Dr. Karen Kelly describes her thought process on which molecular markers are those clearly indicated for  patients with advanced NSCLC, as well as whether smoking status factors into her approach.

[powerpress]

Here's a recent video podcast I just did on the publication just out in Lancet Oncology, describing a randomized phase II study led by my friend Pasi Janne, from Dana Farber Cancer Institute in Boston.

[powerpress]

The report of the phase II randomized trial of MEK inhibitor selumetinib for KRAS mutation-positive NSCLC was just published in Lancet Oncology.  Here's my discussion of some of the highlights of this work and what this means.

[powerpress]

It has been a long time since we've talked about Nexavar (sorafenib), an oral anti-angiogenic targeted therapy that works as a "multi-kinase inhibitor"  and is FDA approved in some other cancers such as renal cell and liver cancer.  In lung cancer, some small, early research done years ago revealed that it has activity in at least a minority of patients with advanced NSCLC.

Historically, lung cancer patients with a KRAS mutation, which is the molecular marker that is actually most common in patients with NSCLC (about 20-25%), have not had extremely appealing treatment options.  In fact, the available data has largely led to the conclusion that both chemotherapy and EGFR inhibitor therapy tends to be, if anything, somewhat less effective for people with a KRAS mutation.  Despite some reason for hope in early research with a few novel therapies, there really hasn't been a good alternative that is specifically effective for KRAS mutation-positive patien